CRIS Current Research Information System

MONGIORGI, SARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.239
EU - Europa 3.773
AS - Asia 3.153
AF - Africa 432
SA - Sud America 160
Continente sconosciuto - Info sul continente non disponibili 17
OC - Oceania 11
Totale 11.785
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.184
IT - Italia 1.127
SG - Singapore 1.111
CN - Cina 795
GB - Regno Unito 657
VN - Vietnam 569
SE - Svezia 508
DE - Germania 506
HK - Hong Kong 228
RU - Federazione Russa 178
IN - India 151
NL - Olanda 133
FR - Francia 126
BR - Brasile 121
TG - Togo 118
SC - Seychelles 112
IE - Irlanda 107
JP - Giappone 87
CI - Costa d'Avorio 83
KR - Corea 65
AT - Austria 57
FI - Finlandia 56
ZA - Sudafrica 56
UA - Ucraina 51
NG - Nigeria 50
BG - Bulgaria 49
EE - Estonia 46
CA - Canada 41
CH - Svizzera 41
HR - Croazia 41
JO - Giordania 35
BE - Belgio 31
ID - Indonesia 22
PL - Polonia 19
EU - Europa 15
AR - Argentina 14
PK - Pakistan 12
BD - Bangladesh 11
IR - Iran 11
ES - Italia 10
TR - Turchia 10
MX - Messico 8
MY - Malesia 8
UZ - Uzbekistan 8
GR - Grecia 7
IL - Israele 7
UY - Uruguay 7
AU - Australia 6
EC - Ecuador 6
LB - Libano 6
LT - Lituania 6
RO - Romania 4
CO - Colombia 3
IQ - Iraq 3
MA - Marocco 3
NZ - Nuova Zelanda 3
TN - Tunisia 3
CL - Cile 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
EG - Egitto 2
KE - Kenya 2
KZ - Kazakistan 2
PE - Perù 2
PH - Filippine 2
PY - Paraguay 2
SK - Slovacchia (Repubblica Slovacca) 2
SS - ???statistics.table.value.countryCode.SS??? 2
TH - Thailandia 2
VE - Venezuela 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AM - Armenia 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
BS - Bahamas 1
CR - Costa Rica 1
CZ - Repubblica Ceca 1
DZ - Algeria 1
GI - Gibilterra 1
GT - Guatemala 1
HU - Ungheria 1
KG - Kirghizistan 1
KW - Kuwait 1
LU - Lussemburgo 1
MD - Moldavia 1
MK - Macedonia 1
MM - Myanmar 1
MU - Mauritius 1
NO - Norvegia 1
NP - Nepal 1
NR - Nauru 1
PA - Panama 1
PS - Palestinian Territory 1
SD - Sudan 1
WS - Samoa 1
Totale 11.785
Salva come PNG Salva come JPEG
Città #
Singapore 768
Southend 560
Ashburn 496
Chandler 456
Bologna 407
Fairfield 367
Santa Clara 272
Hong Kong 228
Ann Arbor 223
Houston 175
Wilmington 168
Woodbridge 156
Princeton 143
Seattle 140
Beijing 126
Cambridge 125
Lomé 118
Dong Ket 111
Boardman 109
Dublin 107
Hefei 89
Dallas 87
Abidjan 83
Ho Chi Minh City 82
Hanoi 69
Milan 63
Padova 63
Frankfurt am Main 62
Westminster 56
Nanjing 55
Tokyo 55
Abeokuta 50
Sofia 49
New York 47
Berlin 45
Los Angeles 45
Vienna 41
Jinan 39
Redwood City 39
Seoul 36
Amman 35
Bern 33
Saint Petersburg 33
Turin 33
Buffalo 32
Helsinki 32
Medford 31
Bremen 30
Brussels 30
Redondo Beach 29
Changsha 26
Moscow 26
Redmond 26
Florence 25
San Diego 25
Munich 24
Nanchang 24
Shenyang 24
London 23
Rome 23
Guangzhou 21
Parma 20
Shanghai 20
Falkenstein 18
Sejong 18
Hebei 17
Jakarta 17
Toronto 17
Amsterdam 15
Chicago 15
Des Moines 14
Nuremberg 14
São Paulo 14
Udine 14
Haiphong 13
Lappeenranta 13
Norwalk 13
Dearborn 12
Falls Church 12
Jiaxing 12
Düsseldorf 11
Hangzhou 11
Montreal 11
Orem 11
Tappahannock 11
Turku 11
Yubileyny 11
Rawalpindi 10
Stockholm 10
Tianjin 10
Warsaw 10
Brooklyn 9
Modena 9
Paris 9
Valsamoggia 9
Zhengzhou 9
Bühl 8
Haikou 8
Kyiv 8
Lanzhou 8
Totale 7.477
Salva come PNG Salva come JPEG
Nome #
Cell signaling pathways in autosomal-dominant leukodystrophy (ADLD): the intriguing role of the astrocytes 306
Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes 257
Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients 238
Prolonged low-dose azacitidine schedule in high-risk MDS patients: Hematologic and molecular response 237
Clinical and molecular insights in erythropoiesis regulation of signal transduction pathways in myelodysplastic syndromes and β-thalassemia 233
Near-peer teaching in human anatomy from a tutors’ perspective: An eighteen-year-old experience at the university of Bologna 223
Nuclear phosphoinositides: Their regulation and roles in nuclear functions 222
Impact of phospholipase C β1 in glioblastoma: a study on the main mechanisms of tumor aggressiveness 218
Inositide-Dependent Nuclear Signalling in Health and Disease 215
A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes 212
Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes 198
Clonal activation of Akt in low-risk MDS patients with del(5q) treated with lenalidomide 196
Molecular Characterization of High-Risk MDS Patients Treated with Azacitidine and Lenalidomide: Role of Inositide-Dependent Signalling, Mutations and Microrna 196
Clonal Effect Of Lenalidomide On Akt Activation In Low-Risk MDS Patients With Del(5q) 195
AZACITIDINE IN MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF LONG-RESPONDER PATIENTS 194
Nuclear inositide signaling and cell cycle 194
Strategic Role of Nuclear Inositide Signalling in Myelodysplastic Syndromes Therapy 191
PLC-β1 and cell differentiation: An insight into myogenesis and osteogenesis 190
AZACITIDINE FOR HIGH RISK MYELODYSPLASTIC SYNDROMES. RETROSPECTIVE EVALUATION OF TWO DIFFERENT DOSING SCHEDULES 189
Nuclear Inositides and Inositide-Dependent Signaling Pathways in Myelodysplastic Syndromes 189
AZACITIDINE IN HIGH AND LOW RISK MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF 57 PATIENTS TREATED WITH 4 DIFFERENT THERAPEUTIC REGIMENS 183
An increased expression of PI-PLCβ1 is associated with myeloid differentiation and a longer response to azacitidine in myelodysplastic syndromes 176
Modulating Phosphoinositide Profiles as a Roadmap for Treatment in Acute Myeloid Leukemia 175
Early Increase of Phospholipase Cbeta1 (PI-PLCbeta1) Gene Expression Predicts Azacitidine Responsiveness in MDS Patients 174
Azacitidine in Myelodysplastic Syndromes: Multicenter Retrospective Study of 34 Long-Responder Patients 174
Nuclear Inositide Signaling via Phospholipase C 172
The wide and growing range of lamin B‑related diseases: from laminopathies to cancer 169
Location-dependent role of phospholipase C signaling in the brain: Physiology and pathology 165
Role of PLCγ1 in the modulation of cell migration and cell invasion in glioblastoma 164
Lamin B1 accumulation’s effects on autosomal dominant leukodystrophy (ADLD): Induction of reactivity in the astrocytes 162
Nuclear phospholipase C beta1 and cellular differentiation. 161
Epigenetic regulation of nuclear inositide signalling in high-risk MDS patients 158
Protein kinase C involvement in cell cycle modulation 157
Emerging Roles of Phospholipase C Beta Isozymes as Potential Biomarkers in Cardiac Disorders 154
DIFFERENTIAL EFFECT OF LENALIDOMIDE ON INDUCTION OF INOSITIDE-DEPENDENT ERYTHROPOIESIS AND CELL CYCLE IN MYELODYSPLASTIC SYNDROMES 153
Effect of Lenalidomide Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients 153
Phosphoinositide-dependent signaling in cancer: A focus on phospholipase C isozymes 153
Nuclear Phosphatidylinositol Signaling: Focus on Phosphatidylinositol Phosphate Kinases and Phospholipases C 152
The whole body donation program at the university of Bologna: A report based on the experience of one of the oldest university in Western world 151
Phospholipase C beta1 (PI-PLCbeta1)/Cyclin D3/protein kinase C (PKC) alpha signaling modulation during iron-induced oxidative stress in myelodysplastic syndromes (MDS) 150
Nuclear PI-PLCβ1 and Myelodysplastic Syndromes: Genetics and Epigenetics 148
Effect of azacitidine on inositide-dependent signalling pathways in low-risk MDS patients 147
Inositide-dependent signaling pathways as new therapeutic targets in myelodysplastic syndromes 145
Subcellular localization relevance and cancer-associated mechanisms of diacylglycerol kinases 144
Role of inositide signalling regulation in higher-risk MDS patients during epigenetic therapy 141
The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation 141
Nuclear inositide signaling in myelodysplastic syndromes. 139
Lamin B1 as a key modulator of the developing and aging brain 138
Synergistic induction of PI-PLCbeta1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes 138
Exploring the controversial role of PI3K signalling in CD4+ regulatory T (T-Reg) cells 138
Epigenetic Regulation of Lipid Signalling Pathways In Low-Risk MDS Patients During Azacitidine Treatment 136
Recent advances in MDS mutation landscape: Splicing and signalling 132
The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resisten human T-acute leukemia cells by a JNK-dependent mechanism 131
Epigenetic regulation of nuclear PLCbeta1 and Cyclin D3 during Azacitidine treatment 129
Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. 128
EFFECT OF LENALIDOMIDE ON INOSITIDE-DEPENDENT SIGNAL TRANSDUCTION PATHWAYS 126
Phosphoinositide-phospholipase C beta1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia. 126
Glycogen Synthase Kinase-3 and phospholipase C-beta signalling: Roles and possible interactions in myelodysplastic syndromes and acute myeloid leukemia 126
PI-PLCbeta-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodysplastic syndromes 125
CLONAL ACTIVATION OF AKT IN LOW-RISK MDS PATIENTS WITH DEL(5Q) TREATED WITH LENALIDOMIDE 124
Understanding the Ultra-Rare Disease Autosomal Dominant Leukodystrophy: an Updated Review on Morpho-Functional Alterations Found in Experimental Models 122
Roles of PI3K/AKT/mTOR Axis in Arteriovenous Fistula 120
Effect of Erythropoietin Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients. 118
Bitter Taste Receptor Agonist Denatonium Inhibits Stemness Characteristics in Hematopoietic Stem/Progenitor Cells 116
Nuclear PI-PLC β1 and Myelodysplastic Syndromes: From Bench to Clinics 115
PROLONGED HEMATOLOGIC AND MOLECULAR RESPONSE AFTER A LIMITED NUMBER OF AZACITIDINE CYCLES IN LOW-RISK MYELODYSPLASTIC SYNDROMES 110
Epigenetic Regulation of Nuclear PI-PLCbeta1 Signalling Pathway in Low-Risk MDS Patients During Azacitidine Treatment 110
GENE EXPRESSION OF INOSITIDE-DEPENDENT SIGNAL TRANSDUCTION PATHWAYS IN MDS PATIENTS WITH DEL(5Q) TREATED WITH LENALIDOMIDE 104
ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) IN MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF LONG-RESPONDER PATIENTS 103
null 103
ROLE OF INOSITIDE-DEPENDENT SIGNAL TRANSDUCTION PATHWAYS ON EPO-INDUCED EYTHROID DIFFERENTIATION IN LOW-RISK MDS PATIENTS 100
null 95
PI-PLCbeta1 Expression in Patients with High-Risk Myelodysplastic Syndromes Is Affected by Azacitidine Treatment. 94
null 81
Nuclear translocation of PKC-alpha is associated with cell cycle arrest and erythroid differentiation in myelodysplastic syndromes (MDSs) 73
null 72
null 71
Current therapy and new drugs: A road to personalized treatment of myelodysplastic syndromes 48
Selective Activation of Nuclear PI-PLCbeta1 During Normal and Therapy-Related Differentiation 47
PKR is activated in MDS patients and its subcellular localization depends on disease severity. 36
Totale 12.089
Salva come PNG Salva come JPEG
Categoria #
all - tutte 33.446
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.446
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021772 0 0 0 0 0 53 65 67 104 47 43 393
2021/20221.707 134 33 81 140 136 77 51 95 74 279 325 282
2022/20232.031 180 265 110 310 169 159 120 151 291 29 130 117
2023/2024840 51 101 82 83 98 121 28 41 74 73 49 39
2024/20252.067 121 272 188 134 350 130 187 90 39 137 97 322
2025/20262.305 363 486 406 276 530 244 0 0 0 0 0 0
Totale 12.089